Exclusive Summary

• The product has the following features: fast onset, rapid metabolism, short and constant half-life of continuous infusion, low incidence of adverse reactions.
• Outstanding Clinical Value: Acting as an 'upgraded Propofol', it offers better hemodynamic stability, no injection pain, and has a specific reversal agent (flumazenil), making it the preferred choice for high-risk and elderly patients.
• Prime Generic Window: With the innovator's core patents expiring in multiple countries and a lack of saturated generic competition overseas, introducing this product now offers a massive 'first-to-file' or early-to-market advantage.
• High Commercial Return: Securing supply from Chinese manufacturers with 'API + FDF' integration guarantees extremely competitive manufacturing costs and ICH-compliant dossiers, providing overseas partners with highly lucrative margins for hospital tenders and commercialization.